Avalo Therapeutics, Inc.
AVTX
$9.88
$0.515.44%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -45.35% | -69.59% | -77.09% | -63.56% | -95.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -45.35% | -69.59% | -77.09% | -63.56% | -95.24% |
| Cost of Revenue | 631.99% | 288.70% | 53.58% | -31.40% | -80.72% |
| Gross Profit | -808.26% | -421.83% | -84.93% | 25.64% | 6.31% |
| SG&A Expenses | 57.58% | 81.65% | 67.36% | 38.73% | 13.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.38% | 137.96% | 62.85% | 4.33% | -38.91% |
| Operating Income | -170.97% | -153.10% | -74.35% | -9.69% | -7.24% |
| Income Before Tax | -27.29% | 151.19% | -11.05% | 75.97% | -46.36% |
| Income Tax Expenses | 853.85% | 784.62% | 714.29% | -129.03% | -53.57% |
| Earnings from Continuing Operations | -27.59% | 151.10% | -11.37% | 76.02% | -46.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.59% | 151.10% | -11.37% | 76.02% | -46.25% |
| EBIT | -170.97% | -153.10% | -74.35% | -9.69% | -7.24% |
| EBITDA | -171.14% | -153.77% | -74.80% | -9.76% | -7.25% |
| EPS Basic | 91.27% | 100.24% | 92.17% | 94.12% | 87.46% |
| Normalized Basic EPS | 94.64% | 133.64% | 96.53% | 97.60% | 91.06% |
| EPS Diluted | 89.82% | 90.16% | 86.73% | 88.93% | 81.92% |
| Normalized Diluted EPS | 96.51% | 103.66% | 74.09% | 84.00% | 74.97% |
| Average Basic Shares Outstanding | 1,181.94% | 1,323.33% | 1,493.00% | 2,317.12% | 1,461.08% |
| Average Diluted Shares Outstanding | 345.19% | 1,940.91% | 2,561.86% | 5,792.17% | 5,029.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |